KPV

Also referred to as Lysine-Proline-Valine peptide, alpha-MSH C-terminal tripeptide.

Status: Investigational. KPV is not an FDA-approved drug product. It is a naturally occurring three-amino-acid fragment (lysine-proline-valine) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH), and research interest centers on its anti-inflammatory signalling properties observed mainly in laboratory and animal models of gut inflammation. Human data are minimal, and no approved product exists for any indication involving this tripeptide.

KPV is the smallest active fragment of alpha-melanocyte-stimulating hormone, consisting of just three amino acids: lysine, proline, and valine. Laboratory and animal research has focused on its apparent anti-inflammatory signalling, particularly in models of intestinal inflammation, independent of the pigmentation and appetite pathways associated with full-length alpha-MSH. It is not an FDA-approved drug product, and published human data are minimal. Interest in KPV should be understood as interest in an actively researched signalling fragment, not an established anti-inflammatory therapy.

What it is

KPV is a tripeptide made of the amino acids lysine, proline, and valine, corresponding to the C-terminal three residues of alpha-MSH. Unlike full-length alpha-MSH, KPV appears in laboratory work to retain some anti-inflammatory signalling activity without the same degree of activity at melanocortin receptors linked to pigmentation and appetite. It is studied as a synthetic research peptide rather than distributed as any approved medical product.

Why people ask about it

Patients interested in gut health and inflammatory conditions sometimes encounter KPV through discussions of alternative approaches to intestinal inflammation, often alongside other investigational peptides. Its small size and specific proposed mechanism, separate from pigmentation effects, make it a frequent topic in online peptide communities. People often want to understand whether the laboratory findings have any bearing on their own inflammatory or gut symptoms.

Proposed mechanism

Laboratory research has proposed that KPV can modulate inflammatory signalling pathways, including effects on NF-kB activity, a transcription factor central to many inflammatory responses, largely demonstrated in cell culture and rodent models of colitis. Because KPV appears to retain some melanocortin-related anti-inflammatory signalling while showing reduced receptor activity linked to pigmentation, researchers have proposed it as a way to isolate anti-inflammatory effects from those cosmetic pathways. These mechanisms remain proposed rather than confirmed, and they are derived almost entirely from cell and animal models of gut inflammation rather than from human pharmacology.

What researchers have studied

  • Rodent models of induced colitis and intestinal inflammation
  • Cell-culture studies of NF-kB and inflammatory cytokine signalling
  • Comparative studies of KPV versus full-length alpha-MSH receptor activity
  • Animal models of skin inflammation
  • Structural studies characterizing the minimal active fragment of alpha-MSH

Human evidence

  • No controlled human clinical trials of KPV for gut or inflammatory conditions have been identified in the published literature.
  • Available data are concentrated in rodent colitis models and cell-culture inflammatory assays, which do not establish human efficacy.
  • Human data are described here as minimal because the tripeptide has not progressed to registered human trials that would allow dosing or safety conclusions.
  • Anecdotal human reports exist online but are not verifiable and should not be treated as evidence.

Preclinical evidence

  • Rodent colitis models have reported reduced markers of intestinal inflammation with KPV exposure.
  • Cell-culture studies have reported decreased inflammatory cytokine signalling in immune cell lines.
  • Comparative receptor-binding studies have reported that KPV shows reduced melanocortin receptor activity linked to pigmentation relative to full-length alpha-MSH.
  • Animal models of skin inflammation have reported reduced inflammatory markers with topical or systemic exposure.
  • These findings remain confined to laboratory and animal systems and have not been replicated in human trials.

What is not yet known

  • Whether KPV produces any measurable anti-inflammatory benefit in humans at any exposure level.
  • What an appropriate human exposure range would be, since none has been studied in controlled trials.
  • Long-term safety of repeated human exposure.
  • How KPV might interact with existing inflammatory bowel disease treatments or immunosuppressive medications.
  • The consistency and purity of unregulated research-grade products sold under this name.
  • Whether the gut-inflammation findings in rodents generalize to human intestinal disease.

Regulatory status and access

KPV does not appear as an independently prescribable product; where discussed with a physician, it would be considered only as one component of a broader physician-selected approach rather than something available on its own. Compounding elsewhere is not the same as FDA approval. Ask about current availability. A physician determines medical appropriateness only after a full evaluation.

Known and potential risks

  • No established human safety profile exists for KPV at any exposure level.
  • Immune-modulating peptides carry a theoretical risk of unpredictable effects on inflammatory or immune balance that have not been characterized in people.
  • Unregulated research-market products carry uncertainty about purity, identity, and sterility.
  • Interaction risk with immunosuppressive or biologic therapies for inflammatory bowel disease is unstudied.
  • Any injectable or unregulated formulation carries contamination and injection-site risks outside pharmaceutical quality control.
  • Marketing claims describing KPV as a gut health solution are not supported by human trial evidence.

Cautions and who may not be a candidate

  • Pregnancy and breastfeeding, given the absence of human safety data.
  • Active infection or immunocompromised states, given unresolved questions about immune signalling effects.
  • Diagnosed inflammatory bowel disease already under active treatment, without physician coordination.
  • Active or suspected malignancy, given unresolved questions about immune and inflammatory pathway modulation.
  • Known hypersensitivity to peptide compounds generally.
  • Use as a substitute for an evaluated, evidence-based inflammatory bowel or dermatologic treatment plan.

Questions to discuss with a physician

  • How does the rodent colitis research relate, if at all, to a condition like mine?
  • What established treatments exist for inflammatory gut or skin conditions that have stronger human evidence?
  • What immune-related risks should I understand before considering a peptide like this?
  • How would this interact with any inflammatory bowel disease medication I currently take?
  • What symptoms would mean I should stop and seek care immediately?
  • Is there a legitimate research pathway through which KPV could become relevant to my care?

Frequently asked questions

Is KPV FDA-approved?

No. KPV is not an FDA-approved drug product for any indication. It is studied as a research peptide, mainly in laboratory and animal models of gut inflammation.

Does GOAL.MD sell KPV?

This page is educational only and does not describe a product for sale. Ask about current availability, and appropriateness is determined only by a physician after evaluation.

What is KPV derived from?

KPV is a three-amino-acid fragment, lysine-proline-valine, that corresponds to the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH).

Does KPV affect pigmentation like alpha-MSH does?

Laboratory comparisons suggest KPV shows reduced activity at melanocortin receptors linked to pigmentation compared with full-length alpha-MSH, though this is based on receptor-binding studies rather than confirmed human effects.

Has KPV been studied in humans?

No, published human data are minimal. Almost all available evidence comes from rodent colitis models and cell-culture inflammatory assays.

What has KPV been studied for in animals?

Animal research has focused on markers of intestinal inflammation in colitis models and inflammatory signalling in skin models.

Is KPV safe?

A human safety profile has not been established. Immune-modulating peptides carry theoretical risks that remain uncharacterized in people.

Can KPV replace my inflammatory bowel disease medication?

No. It should never be treated as a substitute for an evaluated, evidence-based treatment plan, and any interest in it should be discussed with the physician managing that condition.

Can a doctor prescribe KPV?

It is not offered as a standalone prescription product. A physician can discuss the underlying research and whether any legitimate context might ever apply.

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-13.